B Greve1, F Sheikh-Mounessi, B Kemper, I Ernst, M Götte, H T Eich. 1. Klinik und Poliklinik für Strahlentherapie -Radioonkologie, Universitätsklinikum Münster, Albert-Schweitzer Campus 1 Gebäude A1, 48149, Münster, Germany. greveb@uni-muenster.de
Abstract
BACKGROUND AND PURPOSE: Radiotherapy constitutes an essential element in the multimodal therapy of Ewing's sarcoma. Compared to other sarcomas, Ewing tumors normally show a good response to radiotherapy. However, there are consistently tumors with a radioresistant phenotype, and the underlying mechanisms are not known in detail. Here we investigated the association between survivin protein expression and the radiosensitivity of Ewing's sarcoma in vitro. MATERIAL AND METHODS: An siRNA-based knockdown approach was used to investigate the influence of survivin expression on cell proliferation, double-strand break (DSB) induction and repair, apoptosis and colony-forming ability in four Ewing's sarcoma cell lines with and without irradiation. RESULTS: Survivin protein and mRNA were upregulated in all cell lines tested in a dose-dependent manner. As a result of survivin knockdown, STA-ET-1 cells showed reduced cell proliferation, an increased number of radiation-induced DSBs, and reduced repair. Apoptosis was increased by knockdown alone and increased further in combination with irradiation. Colony formation was significantly reduced by survivin knockdown in combination with irradiation. CONCLUSION: Survivin is a radiation-inducible protein in Ewing's sarcoma and its down-regulation sensitizes cells toward irradiation. Survivin knockdown in combination with radiation inhibits cell proliferation, repair, and colony formation significantly and increases apoptosis more than each single treatment alone. This might open new perspectives in the radiation treatment of Ewing's sarcoma.
BACKGROUND AND PURPOSE: Radiotherapy constitutes an essential element in the multimodal therapy of Ewing's sarcoma. Compared to other sarcomas, Ewing tumors normally show a good response to radiotherapy. However, there are consistently tumors with a radioresistant phenotype, and the underlying mechanisms are not known in detail. Here we investigated the association between survivin protein expression and the radiosensitivity of Ewing's sarcoma in vitro. MATERIAL AND METHODS: An siRNA-based knockdown approach was used to investigate the influence of survivin expression on cell proliferation, double-strand break (DSB) induction and repair, apoptosis and colony-forming ability in four Ewing's sarcoma cell lines with and without irradiation. RESULTS: Survivin protein and mRNA were upregulated in all cell lines tested in a dose-dependent manner. As a result of survivin knockdown, STA-ET-1 cells showed reduced cell proliferation, an increased number of radiation-induced DSBs, and reduced repair. Apoptosis was increased by knockdown alone and increased further in combination with irradiation. Colony formation was significantly reduced by survivin knockdown in combination with irradiation. CONCLUSION: Survivin is a radiation-inducible protein in Ewing's sarcoma and its down-regulation sensitizes cells toward irradiation. Survivin knockdown in combination with radiation inhibits cell proliferation, repair, and colony formation significantly and increases apoptosis more than each single treatment alone. This might open new perspectives in the radiation treatment of Ewing's sarcoma.
Authors: Sophie Sokolow; Kristen M Henkins; Iris A Williams; Harry V Vinters; Ingrid Schmid; Gregory M Cole; Karen H Gylys Journal: Cytometry A Date: 2011-12-28 Impact factor: 4.355
Authors: Anne E Carpenter; Thouis R Jones; Michael R Lamprecht; Colin Clarke; In Han Kang; Ola Friman; David A Guertin; Joo Han Chang; Robert A Lindquist; Jason Moffat; Polina Golland; David M Sabatini Journal: Genome Biol Date: 2006-10-31 Impact factor: 13.583
Authors: C Blattmann; M Thiemann; A Stenzinger; A Christmann; E Roth; V Ehemann; J Debus; A E Kulozik; W Weichert; P E Huber; S Oertel; A Abdollahi Journal: Strahlenther Onkol Date: 2013-06-27 Impact factor: 3.621
Authors: Sagar Shelake; Umesh T Sankpal; W Paul Bowman; Matthew Wise; Anish Ray; Riyaz Basha Journal: Invest New Drugs Date: 2016-12-26 Impact factor: 3.850
Authors: E-M Thurner; S Krenn-Pilko; U Langsenlehner; W Renner; A Gerger; K S Kapp; T Langsenlehner Journal: Strahlenther Onkol Date: 2014-01-16 Impact factor: 3.621
Authors: Jordan A Naumann; John C Widen; Leslie A Jonart; Maryam Ebadi; Jian Tang; David J Gordon; Daniel A Harki; Peter M Gordon Journal: Bioconjug Chem Date: 2018-02-19 Impact factor: 4.774
Authors: Dian Huang; Irena J Roy; Graeme F Murray; Jason Reed; Thomas A Zangle; Michael A Teitell Journal: Analyst Date: 2019-12-16 Impact factor: 4.616
Authors: Dominik Bettenworth; Philipp Lenz; Philipp Krausewitz; Markus Brückner; Steffi Ketelhut; Dirk Domagk; Björn Kemper Journal: PLoS One Date: 2014-09-24 Impact factor: 3.240
Authors: Chiara Giorgi; Aleksandar Boro; Florian Rechfeld; Laura A Lopez-Garcia; Maria E Gierisch; Beat W Schäfer; Felix K Niggli Journal: Oncotarget Date: 2015-10-06